Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Urges Investors Suffering Losses Exceeding $100,000 In Regeneron (NASDAQ: ) To Contact Him Directly To Discuss Their Options

If you suffer losses in excess of $100,000 in Regeneron between November 2, 2023 and October 30, 2024 and want to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson direct on 877-247-4292 or 212-983-9330 (Ext. 1310).

(You can also click here for more information)

New York, New York–(Newsfile Corp. – January 9, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc . (“Regeneron” or the “Company”) (NASDAQ: REGN) and reminds investors of March 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Regeneron paid the credit card fees to the distributors on the condition that the distributors did. Eylea customers will not be charged for using a credit card; (2) that these payments subsidize the prices paid by customers to use credit cards to make Eylea purchases; (3) that, as a result, Regeneron offered a price concession that lowered Eylea’s selling price; (4) that, since retina practices are sensitive to higher prices when using credit cards to purchase anti-VEGF drugs, Regeneron’s price concessions provide a competitive advantage; (5) that, as a result of the foregoing, Regeneron misleadingly inflated Eylea’s reported sales; (6) that, by failing to report its payment of credit card charges as price concessions, Regeneron overstated the ASP reported to federal agencies, thereby violating the False Claims Act; and (7) that, as a result of the foregoing, Defendants’ positive statements regarding the Company’s business, operations, and prospects are materially misleading and/or lack a reasonable basis.

On April 10, 2024, the US Department of Justice (“DOJ”) announced that it had filed a complaint against Regeneron under the False Claims Act. According to the DOJ, the Company failed to report millions of dollars in discounts given to drug distributors in the form of refunded credit card payments. As a result, the DOJ alleged that the ASP of Regeneron’s Eylea drug was inflated, inappropriately increasing Medicare payments. By reimbursing credit card fees, Regeneron subsidizes treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments.

On this news, the price of Regeneron shares decreased by $31.50 or 3.36%, in two consecutive trading days to close at $904.70 on April 12, 2024, in unusually heavy trading volume .

Then, on October 31, 2024, before the market opened, Regeneron released its third quarter 2024 financial results, which revealed sluggish US net sales for Eylea HD and Eylea. The Company reported that sales increased by only 3% compared to the third quarter 2023, and quarterly sales of Eylea HD were only $392 million, missing estimates of $415 million to $425 million. The Company also disclosed that “(n)and EYLEA’s product sales in the third quarter of 2024 were affected by a lower net sales price compared to the third quarter of 2023.” Following this news, Reuters reported that the Company “reported weaker-than-expected quarterly sales of a higher-dose version of its blockbuster eye disease drug Eylea.”

On this news, Regeneron’s stock price fell $84.59, or 9.2%, to close at $838.20 per share on October 31, 2024, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is substantially and generally among the class members managing and managing the litigation on behalf of the purported class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain a non-class member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information about Regeneron’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Follow us for updates on LinkedIn, on X, or on Facebook (NASDAQ:).

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict similar results with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated confidentially.

To view the original version of this press release, please visit https://www.newsfilecorp.com/release/236509